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To the Editor,
A 56-year-old male patient who was known to be diagnosed 
with hairy cell leukemia (HCL) and went into remission with 
cladribine 7 years ago was admitted to our clinic due to anemia 
and a leg ulcer. 
One month before his admission, the patient developed weakness 
and exertional dyspnea. On his admission, relapsed leukemia 
with a giant ulcer with irregular borders on the anterior side 
of the left thigh, present for the past 20 days, was diagnosed 
(Figure 1A). At the time of admission, hemoglobin was 7.6 g/
dL and platelet count was 39x109/L. The leukocyte count was 
1.4x109/L with a dominance of lymphocytes (76%). Microscopic 
examination of the marrow and immunophenotyping of 
lymphocytes revealed HCL with characteristic morphology and 
positivity of hairy cell markers like CD25, CD103, and CD11c. 
Infiltration rate with hairy cells was 80%. Meanwhile, no 
environmental causes of an ulcer like an accident, drug use, or 
chemical exposure were identified. The bacterial culture taken 
from the ulcerous surface was negative.
Microscopic examination of the skin biopsy showed 
hyperkeratosis, parakeratosis, acanthosis, edema, spongiosis, 
necrotic keratinocytes, eosinophil and neutrophil exocytosis in the 
epidermis, and a dense inflammatory infiltration extending into 
the subdermal layer. The inflammatory infiltrate was composed 
of eosinophil polymorphs and neutrophil polymorphs. Skin biopsy 
findings were consistent with Sweet’s syndrome (Figure 1B).
While cladribine and pentostatin are known as first treatment 
options for relapsed/refractory HCL, there is not a consensus 
about the use of rituximab in those cases [1].  Therefore, our 
patient underwent splenectomy. The ulcer healed rapidly and 
hematological parameters improved within weeks after the 
splenectomy (Figure 1C). The post-splenectomy complete blood 
count revealed hemoglobin of 11 g/dL, leukocyte count of 
8.6x109/L with 60% lymphocytes, and platelet count of 153x109/L. 
Three months after the splenectomy, when the leg ulcer had 
healed completely, the patient could receive cladribine (0.1 mg/
kg/day  continuous infusion  for  7  days)  successfully to treat 
the disease. Flow cytometric analysis yielded negative minimal 
residual disease in the bone marrow after cladribine. He remains 
leukemia-free at 24 months of follow-up.
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Figure  1. A) A giant ulcer greater than 20 cm in size with an irregular 
margin and tender and hyperemic skin changes arising adjacent 
to the ulcer. B) Photomicrograph reveals the histopathologic 
details of the skin biopsy. The inflammatory infiltration was dense 
and extended to the subdermis (A). There was edema, spongiosis, 
and neutrophil and eosinophil infiltration of the epidermis (B). 
Dermal infiltration was composed of eosinophil polymorphs and 
neutrophil polymorphs (C). Microabscess formation was observed 
(D) [A: Hematoxylin and eosin (H&E), 40x, B: H&E, 200x, C: H&E, 
200x, D: H&E, 200x]. C) Significant improvement of leg ulcer 2 
months after splenectomy.
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The giant leg ulcer in the presented case was uncommon and 
seemed dramatic. In the involved skin, the absence of leukemic 
infiltration, evidence of an infection, or vasculitis pointed 
towards Sweet’s syndrome with typical histological findings.
Several studies have indicated a link between HCL and Sweet’s 
syndrome [2,3]. Although the immunological mechanism is not 
completely defined for Sweet’s syndrome, a chemoattractive 
substance released from leukemic cells may play a role in developing 
neutrophilic tissue infiltration. These substances can be attributed 
to IL-8, leukocyte function antigen, or gamma interferon [2,3,4]. 
For this reason, for complete healing, this lesion required resolution 
of the underlying leukemia. Naturally, the patient was at high risk 
of infection and tissue damage because of the ulcer, so he could 
not receive cladribine for the treatment of HCL. Splenectomy was 
applied to control the leukemic burden. This procedure provided 
leukemia control without using any chemotherapeutic drugs. The 
leukemia went into hematological remission and the ulcer size 
gradually decreased within a few months.
Splenectomy is a historical treatment approach in HCL [5]. This 
treatment nonetheless may still be utilized in patients with 
relapsed or refractory disease.  The rational for splenectomy 
is the minimizing of tumor burden. In addition, it has been 
reported that splenectomy may lead to a decrease in the level of 
some chemokines or cytokines [6,7]. The mechanisms mentioned 
above might be responsible for controlling Sweet’s syndrome 
following splenectomy.
In conclusion, this case reminds us that uncommon manifestations 
may develop in HCL. If so, to control those abnormalities, it 
may be necessary to return to historic treatment strategies in 
situations limiting chemotherapy.
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